C. Hellerbrand et al., INHIBITION OF NFKB IN ACTIVATED RAT HEPATIC STELLATE CELLS BY PROTEASOME INHIBITORS AND AN IKB SUPER-REPRESSOR, Hepatology, 27(5), 1998, pp. 1285-1295
The hepatic stellate cell (HSC), following a fibrogenic stimulus, is t
ransformed from a quiescent to an activated cell. Cytokines induce NF
kappa B activity in activated but not in quiescent HSCs with subsequen
t expression of NF kappa B-responsive genes, such as intercellular adh
esion molecule (ICAM)-1 and interleukin (IL)-6. We investigated the ef
fect of proteasome inhibitors and an I kappa B super-repressor on the
cytokine mediated activation of NF kappa B, ICAM-1, and IL-6 in activa
ted HSCs. Culture-activated HSCs were stimulated with IL-1 beta or tum
or necrosis factor alpha (TNF alpha) in the presence or absence of pro
teasome inhibitors, ALLN or MG-132, or after infection with an adenovi
rus expressing the I kappa B super-repressor (Ad5I kappa B) or beta-ga
lactosidase (Ad5LacZ) as a control. NF kappa B activity was evaluated
by immunofluorescence and by electrophoretic mobility shift assay. The
steady state level of cytoplasmic I kappa B protein was measured by W
estern Blot, ICAM-1 and IL-6 expression was measured by reverse transc
riptase-polymerase chain reaction and enzyme-linked immunosorbant assa
y. Proteasome inhibitors, which block the degradation of I kappa B, an
d the Ad5I kappa B, which provides an exogenous nondegradable I kappa
B, block the stimulation of NF kappa B activity by TNF alpha and IL-1
beta in activated HSCs. These reagents block the subsequent nuclear tr
anslocation of p65 NF kappa B and induction of ICAM-1 and IL-6 by cyto
kines. The specificities of the proteasome inhibitors and the I kappa
B super-repressor are demonstrated by their failure to block c-Jun N-t
erminal kinase induction by cytokines. Cytokine-induced stimulation of
NF kappa B, ICAM-1, and IL-6 is blocked by proteasome inhibitors and
Ad5I kappa B in activated HSCs. Inhibition of I kappa B alpha degradat
ion is a potential target for anti-inflammatory therapy in the liver a
nd might influence the activation process of HSCs following fibrotic s
timuli.